Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Olaparib|DRUG: Durvalumab
Sponsor: Seoul National University Hospital
Collaborators: AstraZeneca